Major Korean vaccine and plasma-derived (blood-product) pharma company, a leading domestic vaccine manufacturer.
Major Korean vaccine and plasma-derived (blood-product) pharma company, a leading domestic vaccine manufacturer.
Sells vaccines largely to Korea's national immunisation programme and the private market, and plasma drugs such as immunoglobulin at home and abroad, so government purchasing and the supply of donor plasma, a scarce input, drive results. Its immunoglobulin Alyglo won US FDA approval in late 2023 and began US sales in 2024.
Moat: narrow (regulatory licence, scale, process know-how). One of few Korean makers with both vaccine and plasma-fractionation manufacturing licenses.
Headquarters: Yongin, South Korea · Founded: 1967 · Employees: 2,351
Size GC Biopharma (006280.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.12B, the 223rd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩130,800 on 18 Nov 2026.
Performance Over six months the shares fell 9.7%, against -11.7% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue fell 3.0% over the last twelve months (peer median -0.9%); the operating margin is 3.6% (peer median 5.6%).
Valuation It trades at 4.6× forward earnings against a peer median of 22.7× (2nd cheapest of 13).
Capital Return on invested capital runs 3.1 points below its cost of capital (5.2% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.88T | ₩1.99T | ₩1.68T | ₩1.63T | ₩1.71T |
| Revenue growth | — | +19% | +3% | -5% | — |
| Gross profit | ₩522B | ₩536B | ₩468B | ₩459B | ₩561B |
| EBITDA | ₩151B | ₩155B | ₩113B | ₩110B | ₩146B |
| Net income | ₩156B | -₩4.67B | -₩26.3B | -₩26.6B | ₩65.5B |
| Free cash flow | -₩90.4B | ₩27.1B | -₩85.5B | -₩84.6B | ₩61.2B |
| Capital expenditure | ₩95.9B | ₩105B | ₩42.4B | ₩126B | ₩94.7B |
| Total debt | ₩848B | ₩982B | ₩828B | ₩724B | ₩576B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| GC Biopharma 006280.KS | $1.12B | -10% | -3% | 4% | 4.6× | n/a |
| SKBS 302440.KS | $2.25B | -12% | +11% | -23% | n/a | n/a |
| CSL CSL.AX | $63.7B | +102% | -2% | 26% | 21.5× | 6.8% |
| Grifols GRF.MC | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 006280.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.4% | -2.3% | 9th highest of 21 |
| 6-month return | -9.7% | -11.7% | 10th highest of 20 |
| Distance from 52-week high | -28.1% | -33.1% | 9th highest of 21 |
| Revenue growth (TTM) | -3.0% | -0.9% | 8th lowest of 18 |
| Operating margin | 3.6% | 5.6% | 9th lowest of 19 |
| Forward P/E | 4.6× | 22.7× | 2nd cheapest of 13 |
| ROIC minus cost of capital | -3.1 pp | -3.7 pp | 10th highest of 19 |
| EV / EBITDA | 14.9× | 13.2× | 3rd most expensive of 6 |
| Net debt / EBITDA | 4.5× | -1.7× | most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 4.6× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 32.2× | 36.3% | +20.4% |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 27.8× | 4.2% | +21.7% |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 418.7× | n/a | n/a |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 18.1× | 4.9% | +11.3% |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% | +4.2% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 18.4× | 3.4% | -1.2% |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 14.5× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | n/a | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% | -9.0% |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | n/a | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | n/a | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 60.4× | n/a | n/a |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |